Therapeuticsmd Stock Today

TXMD Stock  USD 0.77  0.04  5.48%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

High

 
High
 
Low
TherapeuticsMD is trading at 0.77 as of the 18th of March 2025, a 5.48 percent increase since the beginning of the trading day. The stock's lowest day price was 0.72. TherapeuticsMD has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of December 2003
Category
Healthcare
Classification
Health Care
TherapeuticsMD, Inc. operates as a womens healthcare company in the United States. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. Therapeuticsmd operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 11.53 M outstanding shares of which 155.75 K shares are at this time shorted by private and institutional investors with about 0.3 trading days to cover. More on TherapeuticsMD

Moving together with TherapeuticsMD Stock

  0.75ME 23Andme HoldingPairCorr
  0.8VANI Vivani Medical Earnings Call This WeekPairCorr

Moving against TherapeuticsMD Stock

  0.58DVAX Dynavax TechnologiesPairCorr
  0.57VALN Valneva SE ADR Earnings Call TodayPairCorr
  0.41SRZNW Surrozen WarrantPairCorr

TherapeuticsMD Stock Highlights

Co-Founder, CEO and DirectorRobert Finizio
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
TherapeuticsMD can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand TherapeuticsMD's financial leverage. It provides some insight into what part of TherapeuticsMD's total assets is financed by creditors.
Liquidity
TherapeuticsMD currently holds 8.01 M in liabilities with Debt to Equity (D/E) ratio of 0.67, which is about average as compared to similar companies. TherapeuticsMD has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about TherapeuticsMD's use of debt, we should always consider it together with its cash and equity.

Change In Cash

(38.47 Million)
TherapeuticsMD (TXMD) is traded on NASDAQ Exchange in USA. It is located in 951 Yamato Road, Boca Raton, FL, United States, 33431 and employs 1 people. TherapeuticsMD is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.36 M. TherapeuticsMD conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 11.53 M outstanding shares of which 155.75 K shares are at this time shorted by private and institutional investors with about 0.3 trading days to cover. TherapeuticsMD currently holds about 27.08 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check TherapeuticsMD Probability Of Bankruptcy
Ownership Allocation
30% of TherapeuticsMD outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check TherapeuticsMD Ownership Details

TherapeuticsMD Stock Institutional Holders

InstituionRecorded OnShares
Ameriprise Financial Inc2024-12-31
22.5 K
Northern Trust Corp2024-12-31
16.5 K
J. Goldman & Co Lp2024-12-31
13.6 K
Renaissance Technologies Corp2024-12-31
10.9 K
Fmr Inc2024-12-31
8.3 K
Tower Research Capital Llc2024-12-31
4.8 K
Ubs Group Ag2024-12-31
K
Group One Trading, Lp2024-12-31
1.1 K
Bank Of America Corp2024-12-31
494
Rubric Capital Management Lp2024-12-31
1.2 M
Clearline Capital Lp2024-12-31
635.2 K
View TherapeuticsMD Diagnostics

TherapeuticsMD Historical Income Statement

At present, TherapeuticsMD's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 738 K, whereas Total Revenue is forecasted to decline to about 1.4 M. View More Fundamentals

TherapeuticsMD Stock Against Markets

TherapeuticsMD Corporate Management

Hugh MBAPres DirectorProfile
MD FACOGCoFounder,CoCEO OfficerProfile
Douglas SteelmanVice AccessProfile
Benjamin FoulkVice ResourcesProfile
Dedra LydenVice InitiativesProfile
Joseph ZieglerPrincipal OfficerProfile
Daniella SilvaChief OfficerProfile
When determining whether TherapeuticsMD is a strong investment it is important to analyze TherapeuticsMD's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact TherapeuticsMD's future performance. For an informed investment choice regarding TherapeuticsMD Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TherapeuticsMD. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TherapeuticsMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.35)
Revenue Per Share
0.14
Quarterly Revenue Growth
(0.47)
Return On Assets
(0.07)
Return On Equity
(0.14)
The market value of TherapeuticsMD is measured differently than its book value, which is the value of TherapeuticsMD that is recorded on the company's balance sheet. Investors also form their own opinion of TherapeuticsMD's value that differs from its market value or its book value, called intrinsic value, which is TherapeuticsMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TherapeuticsMD's market value can be influenced by many factors that don't directly affect TherapeuticsMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.